et of Alzheimer's disease is being recognized.
Research in Alzheimer's
disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.
Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Selected 185 clinical trials are listed, of which 131 are still in progress and 54 were discontinued for various reasons.
Alzheimer's disease market in the seven major markets is analyzed for the year 2012. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2022. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.
Profiles of 144 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 97 collaborations. The bibliography contains over 850 publications that are cited in the report.The report is supplemented with 45 tables and 15 figures.
Key Topics Covered:
1. Clinical Features, Epidemiology and Pathology
2. Diagnostic Procedures for Alzheimer Disease
3. Management of Alzheimer Disease
4. Research in Alzheimer Disease
5. Drug Discovery & Development for Alzheimer Disease
6. Markets & Finances of AD Care<Page: 1 2 3 Related biology technology :1
. Modeling Alzheimers disease using iPSCs2
. Is There a Natural Cure for Alzheimer's and Other Dementias?3
. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space4
. Leuven research opens new pathway for the treatment of Alzheimers disease 5
. World Alzheimers Day - 21 September 20126
. Alzheimers Therapeutics Reviewed by NeuroPerspective7
. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit8
. First detailed timeline established for brains descent into Alzheimers9
. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair10
. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline11
. Scientists gain new understanding of Alzheimers trigger